ARF

:   acute renal failure

CPA

:   cardiopulmonary arrest

CPCR

:   cardiopulmonary cerebral resuscitation

CrCl

:   creatinine clearance

CRI

:   continuous rate infusion

CRRT

:   continuous renal replacement therapy

RRT

:   renal replacement therapy

URR

:   urea reduction rate

A 1‐hour‐old 64.1 kg Thoroughbred filly was presented to Iowa State University\'s Lloyd Veterinary Medical Center because the foal was unresponsive since birth. Gestation was reportedly normal, but parturition was not observed. At presentation, the foal was unresponsive, apneic, bradycardic (32 beats/min), and hypothermic (\<92°F). Considerable hemorrhaging from the umbilicus was noted until the external umbilicus was tied with suture. Palpebral and corneal reflexes were absent, and peripheral arterial pulses were undetectable. Venous blood gas analysis revealed severe acidosis, hypercarbia, and hyperlactatemia (Table [1](#jvim14665-tbl-0001){ref-type="table-wrap"}). The foal was resuscitated with 3 doses of epinephrine[1](#jvim14665-note-1001){ref-type="fn"} (0.008 mg/kg, IV) administered at 10‐minute intervals, a constant rate infusion (CRI) of dobutamine[2](#jvim14665-note-1002){ref-type="fn"} (2 μg/kg/min, IV), and IV fluid therapy (isotonic fluids[3](#jvim14665-note-1003){ref-type="fn"} \[30 mL/kg\], synthetic colloids[4](#jvim14665-note-1004){ref-type="fn"} \[4 mL/kg\]). Nasotracheal intubation and manual ventilation and supplemental oxygen was also provided. Equine whole blood (15 mL/kg) was administered at 2 hours of age to treat anemia secondary to umbilical hemorrhage. At 4 hours of age, the foal was responsive with a regular and voluntary breathing pattern. Serial blood gas and serum biochemistry analysis are presented in Tables [1](#jvim14665-tbl-0001){ref-type="table-wrap"} and [2](#jvim14665-tbl-0002){ref-type="table-wrap"}. The foal began to rise and suckle on her own and ceftiofur[5](#jvim14665-note-1005){ref-type="fn"} (5 mg/kg IV q12h) and 1 L of normal equine plasma was administered IV. Over the next 12 hours, the foal was administered 300 mL IV boluses of lactated Ringer\'s solution[6](#jvim14665-note-1006){ref-type="fn"} with 2.5% dextrose every 2 hours and assisted to suckle hourly.

###### 

Clinicopathologic data from a newborn foal during and after the immediate postresuscitation period

  Foal Age (hours)                1[a](#jvim14665-note-0001){ref-type="fn"}   1.5[a](#jvim14665-note-0001){ref-type="fn"}   2[b](#jvim14665-note-0002){ref-type="fn"}   2.5[a](#jvim14665-note-0001){ref-type="fn"}   3[a](#jvim14665-note-0001){ref-type="fn"}   4[b](#jvim14665-note-0002){ref-type="fn"}   12[a](#jvim14665-note-0001){ref-type="fn"}   Reference Interval[a](#jvim14665-note-0001){ref-type="fn"}
  ------------------------------- ------------------------------------------- --------------------------------------------- ------------------------------------------- --------------------------------------------- ------------------------------------------- ------------------------------------------- -------------------------------------------- ------------------------------------------------------------
  pH                              6.604                                       6.721                                         6.971                                       7.027                                         7.223                                       7.262                                       7.347                                        7.34--7.36
  pCO~2~ (mmHg)                   100.0                                       53.8                                          39.3                                        63.4                                          43.0                                        52.4                                        56.4                                         42.3--48.1
  pO~2~ (mmHg)                    56.2                                        62.3                                          194.1                                       59.3                                          56.4                                        95.3                                        37.1                                         34.7--45.3
  SO~2~ (%)                       41.5                                        57.6                                          98.4                                        73.3                                          82.1                                        96.0                                        64.4                                         64.7--83.1
  HCT (%)                         20                                          17                                            14                                          16                                            22                                          25                                          22                                           37--49
  $\text{HCO}_{3}^{-}$ (mmol/L)   10.0                                        7.0                                           9.1                                         16.8                                          17.9                                        23.8                                        31.2                                         27.6--30.7
  Lactate (mmol/L)                17.4                                        16.5                                          14.3                                        13.0                                          13.8                                        14.8                                        5.1                                          1.9--5.7

Venous blood.

Arterial blood.

John Wiley & Sons, Ltd

###### 

Clinicopathologic data[a](#jvim14665-note-0004){ref-type="fn"} from a postresuscitation foal with acute renal failure before, during, and after a 6‐hour CRRT session. Reference interval for serum samples

  Foal Age (hours)                1     4     24     48    72    76    80     81      82     96      Ref Interval          
  ------------------------------- ----- ----- ------ ----- ----- ----- ------ ------- ------ ------- -------------- ------ ------------
  Na+ (mEq/L)                     139   140   135    129   127   127   128    *124*   127    *124*   127            125    137--145
  K+ (mEq/L)                      5.4   3.6   3.7    3.8   4.5   4.5   4.4    *4.1*   4.3    *4.1*   4.9            5.1    2.7--4.8
  Cl− (mEq/L)                     109   94    94     90    89    89    94     *99*    94     *100*   96             95     102--114
  Phos (mg/dL)                    --    --    6.1    5.0   6.3   6.3   5.5    *3.6*   5.6    *3.5*   5.6            6.1    2.6--5.0
  Ca++ (mg/dL)                    --    --    10.0   9.2   11    11    11.5   *8.0*   11.7   *8.3*   12             11.4   10.6--12.8
  $\text{HCO}_{3}^{-}$ (mmol/L)   10    18    34     33    33    33    25     *20*    26     *18*    22             22     24.5--33.5
  BUN (mg/dL)                     17    15    32     41    63    63    46     *35*    48     *32*    42             61     14--21
  Creat (mg/dL)                   2.7   2.8   6.4    8     10    10    7.5    *5.3*   7.6    *4.7*   6.7            8.3    1.0--2.1

Vitros 5,1 FS Chemistry System, Ortho Clinical Diagnostics, Raritan, NJ

Number in italics indicate values for effluent

John Wiley & Sons, Ltd

The following morning (24 hours old), the foal was alert and responsive but had not produced any urine. Serum biochemistry profile documented azotemia along with electrolyte alterations (Table [2](#jvim14665-tbl-0002){ref-type="table-wrap"}); abnormalities on CBC included anemia (hematocrit 21%; reference range, 37--49%) and low hemoglobin (7.1 g/dL; reference range, 12.6--17.4 g/dL). The serum IgG concentration was 480 mg/dL (adequate transfer of maternal antibodies \>800 mg/dL); therefore, another 1 L of equine plasma was administered IV, subsequently raising the serum IgG to \>800 mg/dL. Ultrasonographic examination revealed a small urinary bladder whereas the kidneys appeared normal. To promote urine production, furosemide[7](#jvim14665-note-1007){ref-type="fn"} (1 mg/kg q4h × 4 doses) and mannitol[8](#jvim14665-note-1008){ref-type="fn"} (500 mg/kg of a 20% solution over 15 minutes q6h for 2 doses) were administered IV. At 48 hours of age, the foal still had not urinated and an indwelling urinary catheter was placed which yielded a small amount (\<10 mL) of urine. Hematuria and isosthenuria (specific gravity of 1.008) were noted on urinalysis. Evidence of fluid retention was manifested as an increase of 9.1 kg body weight (73.2 kg) and development of facial, pectoral, and limb edema. The foal produced approximately 20 mL of urine over a 12‐hour period. Further attempts to promote urine production included administration of a furosemide CRI (0.12 mg/kg/h IV). At 72 hours of age, the foal was ambulatory and alert, but due to progressive azotemia and fluid retention, renal replacement therapy (RRT) was elected with the goals of partial removal of excess body fluid and partial correction of azotemia to allow added time for the kidneys to regain function.

The foal was sedated with diazepam[9](#jvim14665-note-1009){ref-type="fn"} (0.08 mg/kg IV) and a 14 French, 28 cm, double lumen hemodialysis catheter[10](#jvim14665-note-1010){ref-type="fn"} was placed in the jugular vein using the Seldinger technique and venous cutdown. The foal was administered a bolus (100 IU/kg) followed by a CRI (50 IU/kg/h) of unfractioned heparin[11](#jvim14665-note-1011){ref-type="fn"} and a commercial acrylonitrile‐sodium methallyl sulfonate copolymer hollow‐fiber hemodiafiltration set[12](#jvim14665-note-1012){ref-type="fn"} with a surface area of 1.5 m^2^ was used with the noted initial RRT settings: blood flow rate of 50 mL/min, dialysate rate of 4000 mL/h, postfilter fluid replacement rate of 4000 mL/h and patient fluid removal rate of 300 mL/h (Table [2](#jvim14665-tbl-0002){ref-type="table-wrap"}). Plasmalyte[3](#jvim14665-note-1003){ref-type="fn"} was used as the dialysate and replacement fluid. A 6‐hour intermittent hemodiafiltration treatment was administered utilizing a continuous renal replacement therapy (CRRT) machine[13](#jvim14665-note-1013){ref-type="fn"} with vital parameters recorded every 30 minutes. The blood flow rate through the CRRT machine was gradually increased to a maximum of 280 mL/min and the patient fluid removal rate increased from 300 to 600 mL/h. The heart rate (mean 97 beats/min; range 80--100 beats/min) and respiratory rate (mean 28 breaths/min; range 12--44 breaths/min) remained stable but rectal temperature declined from 101.3◦F at the start of the session to 94.6◦F at the end. The PT and aPTT after 3 hours of RRT was 18.5 seconds (reference interval, 14.3--18.4 seconds) and 160 seconds (reference interval, 49.9--69.4 seconds), respectively. The foal suckled from the mare every 2 hours while being connected to the CRRT machine. The total fluid removal from the foal during the RRT session was 1703 mL correlating with a 1.1 kg loss in body weight (72.1 kg). The BUN and serum creatinine concentrations decreased from 63 mg/dL and 10 mg/dL, respectively, at the start of RRT to 42 mg/dL and 6.7 mg/dL at the end of RRT, respectively. The foal remained oliguric during the RRT session producing approximately 50 mL of urine over the 6‐hour session.

The creatinine clearance (CrCl), representing the volume of blood cleared of creatinine per minute excretion of urine (or in the case of RRT, effluent), was calculated. Because of mislabeled samples, CrCl was only calculated over the 4th and 5th hour time periods (Tables [2](#jvim14665-tbl-0002){ref-type="table-wrap"} and [3](#jvim14665-tbl-0003){ref-type="table-wrap"}) using the following formula:

###### 

Renal replacement data for a foal with acute renal failure. Total procedure time was 6 hours and 40 minutes with a 5‐hour and 2‐minutes actual run time.[a](#jvim14665-note-0004){ref-type="fn"}

  RRT (hours)                        Start   1       2       3       4       5       6       7       Total
  ---------------------------------- ------- ------- ------- ------- ------- ------- ------- ------- --------
  Patient Fluid Removal (mL)         0       72      171     239     300     345     425     151     1,703
  Replacement Fluid Prefilter (mL)   0       1,267   3,614   3,772   3,297   3,080   3,399   1,190   19,619
  Dialysate (mL)                     0       1,261   3,610   3,816   3,289   3,060   3,397   1,188   19,621
  Effluent (mL)                      0       3,394   7,395   7,827   6,886   6,485   7,221   2,529   41,737

Procedure time indicates the total time in which patient was interfaced with RRT machine; run time indicates time in which blood was being processed through filter but does not include time where system was on standby to allow for fluid bag changes, empting of effluent bags, and correcting alarms.

John Wiley & Sons, Ltd

$$\left\lbrack {\text{CrCl} = \frac{\text{Ultrafiltrate\ [Cr]}}{\text{Plasma\ [Cr]}} \times \frac{\text{Effluent\ output\ [mL]}}{\text{Time\ [minutes]}}} \right\rbrack$$

The urea reduction ratio (URR), representing the percentage decrease in urea over the RRT session, was calculated using the following formula:

$$\text{URR} = \frac{\text{pre‐BUN} - \text{post‐BUN}}{\text{pre‐BUN}} \times 100$$

The CrCl over the 4th and 5th hour times were 81.1 and 66.8 mL/min of effluent, respectively. Creatinine clearance expressed based on body weight (mL/kg/min) was 1.27 and 1.04 mL/kg/min, respectively. The URR over the CRRT session was 33%.

During and after the RRT session, the foal was continued on the CRI of furosemide. The body temperate returned to 100.6◦F 6 hours after completion of the RRT session, and vital parameters were within acceptable ranges. The foal produced approximately 90 mL of urine over the next 12 hours; however, the following morning (96 hours old), the foal\'s BUN and serum creatinine increased to 61 mg/dL and 8.3 mg/dL, respectively and the body weight increased to 76.4 kg along with worsened facial, pectoral and limb edema. Furthermore, labored respiratory effort (respiratory rate 32 breaths/min) and blood‐tinged froth were noted from both nares. Based on the deterioration of clinical condition, continued lack of substantial urine production, exhausted financial resources, and poor prognosis, the foal was euthanized.

Postmortem examination confirmed diffuse subcutaneous, pulmonary, and renal edema with tri‐cavitary effusion. The lungs, kidneys, and heart had multifocal petechial hemorrhages and generalized loss of body fat was present. Microscopic changes within the kidney included multifocal infarction associated with multiple intravascular thrombi and necrosis and sloughing of tubular epithelial cells accompanied by evidence of epithelial cell regeneration. Centrilobular necrosis was present within the liver, and multifocal neuronal necrosis was identified within the brain. This constellation of lesions was interpreted as secondary to hypoxic injury. In addition to pulmonary edema, a mild bronchopneumonia with intra‐alveolar squames was observed, with the latter observation considered indicative of in‐utero stress.

The equine industry involves a continuous cycle of breeding mares and monitoring pregnancy and parturition leading to the common presentation of newborn foals in various levels of critical illness, and at times cardiopulmonary arrest (CPA), to equine clinicians. To date, very few case reports describing CPCR in foals have been published in the literature and the low numbers of cases that have been described have not survived the initial CPA.[1](#jvim14665-bib-0001){ref-type="ref"} As a result of the dearth of reported cases, postresuscitation complications have not been detailed in foals, as compared to the numerous complications, commonly referred to as postcardiac arrest syndrome, observed in people.[2](#jvim14665-bib-0002){ref-type="ref"}, [3](#jvim14665-bib-0003){ref-type="ref"}, [4](#jvim14665-bib-0004){ref-type="ref"} These complications include brain injury, myocardial dysfunction, and acute kidney injury (AKI).[2](#jvim14665-bib-0002){ref-type="ref"}, [3](#jvim14665-bib-0003){ref-type="ref"}, [4](#jvim14665-bib-0004){ref-type="ref"} Organ dysfunction results from a combination of insults including ischemia‐reperfusion injury and the systemic inflammatory response syndrome.[2](#jvim14665-bib-0002){ref-type="ref"}, [3](#jvim14665-bib-0003){ref-type="ref"}, [4](#jvim14665-bib-0004){ref-type="ref"} Cytokines, adhesion molecules, impaired vasoregulation, increased coagulation and endotoxin contribute to organ injury, dysfunction and potentially organ failure.[2](#jvim14665-bib-0002){ref-type="ref"}, [3](#jvim14665-bib-0003){ref-type="ref"}, [4](#jvim14665-bib-0004){ref-type="ref"} The reported incidence of AKI in people after CPA and CPCR ranges from 12 to 80%, depending on how AKI is defined.[3](#jvim14665-bib-0003){ref-type="ref"}, [5](#jvim14665-bib-0005){ref-type="ref"}, [6](#jvim14665-bib-0006){ref-type="ref"}, [7](#jvim14665-bib-0007){ref-type="ref"} The duration of postresuscitation hypotension might be associated with AKI as hypotension was significantly longer in people with AKI as compared to the non‐AKI group.[3](#jvim14665-bib-0003){ref-type="ref"} The complete mechanism by which AKI develops post‐CPA and CPCR is not fully elucidated; however, initial ischemic injury to the kidney during CPA and resuscitation might cause sublethal renal tubular injury; subsequently, reperfusion injury, hypoperfusion, or both from circulatory shock may result in further injury.[3](#jvim14665-bib-0003){ref-type="ref"}, [7](#jvim14665-bib-0007){ref-type="ref"} In the case here, ischemia and low oxygen carrying capacity due to low hemoglobin concentration along with increased activity of the coagulation system likely contributed to the development of acute renal failure (ARF) as tubular necrosis, a lesion related to ischemia, as well as multifocal infarction and intravascular thrombi were noted on microscopic examination.[8](#jvim14665-bib-0008){ref-type="ref"} The lack of thrombi within other organs suggests that the renal thrombi were secondary to renal damage or a direct cause of AKI rather than a systemic coagulopathy. Further microscopic evidence of ischemia included injury to the central nervous system (neuronal necrosis) and liver (centrilobular necrosis), but clinical manifestations of these lesions were not apparent. Another variable that might contribute to development of AKI in this case was the administration of hetastarch, which has been associated with AKI and decreased outcome in dogs;[9](#jvim14665-bib-0009){ref-type="ref"} however, nephrotoxicity has not been demonstrated in equine patients.

Renal replacement therapy including intermittent hemodialysis, intermittent hemodiafiltration, CRRT, and peritoneal dialysis, has been rarely implemented in adult horses and foals.[10](#jvim14665-bib-0010){ref-type="ref"}, [11](#jvim14665-bib-0011){ref-type="ref"}, [12](#jvim14665-bib-0012){ref-type="ref"}, [13](#jvim14665-bib-0013){ref-type="ref"} In 1 case, a 4‐day‐old foal with oxytetracycline‐induced ARF was anesthetized on 3 separate occasions to allow intermittent hemodialysis treatments over a 4‐day period and was reportedly healthy at 2 years of age.[12](#jvim14665-bib-0012){ref-type="ref"} Intermittent and continuous peritoneal dialysis has also been used in a few horses to treat ARF with some success.[10](#jvim14665-bib-0010){ref-type="ref"}, [13](#jvim14665-bib-0013){ref-type="ref"} Hemodiafiltration is a blood purification modality available on CRRT machines and is similar to intermittent hemodialysis in that the patient\'s blood is passed through thousands of straw‐like semipermeable membranes contained within a dialyzer.[14](#jvim14665-bib-0014){ref-type="ref"} However, in addition to diffusion principles that promote blood purification in intermittent hemodialysis, hemodiafiltration uses convection (solvent drag) and adsorption (adhesion) to facilitate blood purification.[14](#jvim14665-bib-0014){ref-type="ref"}, [15](#jvim14665-bib-0015){ref-type="ref"} Hemodiafiltration employs a slow and gradual purification process, as compared to intermittent hemodialysis, allowing better control of blood pressure, electrolyte changes and acid--base balance and can also remove fluid volume overload as well as assist in clearance of nephrotoxic drugs, toxins, and toxic metabolites.[15](#jvim14665-bib-0015){ref-type="ref"}, [16](#jvim14665-bib-0016){ref-type="ref"} The foal presented here tolerated the RRT procedure well for the 6‐hour session and was maintained in lateral recumbency by hospital staff during the procedure; additional sedation or anesthesia was not required. Furthermore, RRT continued while the foal nursed, with manual restraint, for short periods of time. The foal did become hypothermic, which is a recognized adverse effect of dialysis procedures as extracorporeal blood is exposed to cooler ambient temperatures and RRT fluids, resulting in cooler blood being returned to the foal.[17](#jvim14665-bib-0017){ref-type="ref"} Warm air blankets were applied to the foal and the foal\'s body temperature returned to baseline within hours of completion of the RRT session. Initially, the blood flow rate through the CRRT filter was set at 50 mL/min and was gradually increased to a maximum of 280 mL/min. Higher rates (\>300 mL/min) were attempted, but the high‐pressure indicator from the efferent catheter access port (i.e blood being removed from patient) would alarm, suggesting that the jugular vein was collapsing on the catheter at higher blood extraction flow rates.

No published information is available for an anticoagulant dose of heparin during RRT in neonatal foals, although 1 case used a loading dose of heparin (100 IU/kg) followed by hourly boluses of 20 IU/kg.[12](#jvim14665-bib-0012){ref-type="ref"} In the case here, the same loading dose was used (100 IU/kg bolus), followed by a CRI recommended for adult horses (50 IU/kg/h), and appeared to be a sufficient to prevent clotting over the 6‐hour RRT session.[11](#jvim14665-bib-0011){ref-type="ref"}, [18](#jvim14665-bib-0018){ref-type="ref"} The activated clot time (ACT) is used to evaluate the efficacy of anticoagulants during dialysis procedures with an ACT of 150--180 seconds targeted in small animal patients.[19](#jvim14665-bib-0019){ref-type="ref"} The ACT was not available in the case presented here; therefore, PT and PTT were used to evaluate the coagulation system during the RRT session. Ideally, baseline PT and PTT should have been measured but did not occur in this case. The prolongation of the PT in the case described here (18.5 seconds) was similar to healthy adult horses (mean PT 20.6 seconds); however, prolongation of the PTT (160 seconds) was not as dramatic as healthy adult horses (PTT \> 245 seconds) despite using the same dose of heparin.[11](#jvim14665-bib-0011){ref-type="ref"} A difference in the pharmacokinetics or pharmacodynamics to heparin might explain the differences noted between adult horses and neonatal foals.[20](#jvim14665-bib-0020){ref-type="ref"} Subjectively, anticoagulation was adequate for the case here as there was no evidence of clotting within the dialyzer (dark blood, blood streaks or fibrin) nor increased pressures within the circuit.[21](#jvim14665-bib-0021){ref-type="ref"}

The CrCl in the foal presented here was 81.1 and 66.8 mL/min of effluent, over the 4th and 5th hours respectively, as compared to an average of 68.9 mL/min of effluent in healthy adult horses.[11](#jvim14665-bib-0011){ref-type="ref"} In comparison, 1 report described a CrCl of 40.9 mL/min and 12.5 mL/min with continuous and intermittent peritoneal dialysis, respectively, in an adult horse with ARF.[10](#jvim14665-bib-0010){ref-type="ref"} However, when body weight of the patient is considered, the CrCl in this report (1.27 and 1.04 mL/kg/min) was much higher than that measured in healthy adult horses (0.127 mL/kg/min) undergoing a similar RRT session, thus suggesting that RRT has more potential to effectively treat azotemia in foals as a result of their smaller blood volume as compared to adult horses.[11](#jvim14665-bib-0011){ref-type="ref"} Additionally, CrCl in the foal in this report was more efficient than peritoneal dialysis described in adult horses which documented a CrCl of 0.105 mL/kg/min and 0.03 mL/kg/min with continuous and intermittent peritoneal dialysis, respectively.[10](#jvim14665-bib-0010){ref-type="ref"} Moreover, both the serum creatinine concentration and BUN (URR) dropped by 33% over the RRT session in the foal presented here. Of note, the case presented here was treated on an emergency basis, which prohibited more calculated sample and data collections. Therefore, solute clearance could only be calculated at arbitrary time points. While a full discussion regarding the factors that contribute to clearance of uremic solutes is beyond the scope of this case report, the variables reported (i.e prereplacement fluid, dialysate, effluent) are reported to illustrate relevant dialysis prescription parameters that are determinants of solute clearance and serve as a starting point for future cases. With the feasibility of this RRT platform demonstrated in this case, the opportunity to better characterize solute clearance should be seized in the future.

Fluid retention was noted in the foal described here, evidenced by 9.1 kg gain in body weight and generalized edema over the first 48 hours of life. During the RRT session, total fluid removal from the foal (1703 mL) correlated with a 1.1 kg loss in body weight (72.1 kg), suggesting that intermittent hemodiafiltration can effectively remove excess fluid volume from neonatal foals with volume overload. Renal replacement therapies are designed to remove fluid from the intravascular compartment, but hemodynamic stability is dependent on refilling of the intravascular space with fluid from the interstitium.[21](#jvim14665-bib-0021){ref-type="ref"} The speed at which the intravascular space is replenished (plasma refill rate) dictates and limits the amount of intravascular fluid that can be removed.[21](#jvim14665-bib-0021){ref-type="ref"} Hemodiafiltration allows slow and constant removal of fluid from the patient, providing hemodynamic stability as excess fluid is removed whereas intermittent hemodialysis is associated with more rapid fluid shifts and less hemodynamic stability.[20](#jvim14665-bib-0020){ref-type="ref"} Thus, hemodiafiltration may be a therapy for treating hypervolemia in horses with AKI or congestive heart failure.

In summary, although the foal in this report did not survive, this report highlights RRT as a novel and viable therapeutic option for foals with ARF. Although the incidence of CPA and postcardiac arrest syndrome in foals is not known, clinicians and support staff should be familiar with CPCR techniques, maintain a properly equipped facility to allow rapid administration of CPCR and be aware of postcardiac arrest complications. In addition, RRT may be a viable option to facilitate recovery from anuric or oliguric ARF and facilitate removal of excess fluid volume in neonatal foals. In retrospect, longer (i.e 10--12 hours) and repeated (2--4 sessions) RRT session may have improved outcome and allowed further correction of azotemia and removal of excess fluid from the patient, both of which might have provided more time to recover renal function. This point serves to highlight some of the current limitations of RRT in foals to allow modification of this treatment modality in future clinical cases. First, treatment times must be extended to allow adequate time for solute and excess fluid removal. Second, a team of veterinarians and support staff must be available to perform extended or continuous treatments. Lastly, RRT‐induced hypothermia must be addressed by warming fluids involved in RRT along with provision of external methods of warming the patient. Notwithstanding, this case is the first to describe the postcardiac arrest complications (ARF) and RRT in a neonatal foal, but further investigation are needed to advance equine critical care.
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